Gabriele Reinartz1, Hans Theodor Eich, Fabian Pohl. 1. Department of Radiation Oncology, University Hospital Muenster, Albert Schweitzer Campus 1, 48149, Muenster, Germany, gabriele.reinartz@ukmuenster.de.
Abstract
PURPOSE: To summarize the updated DEGRO consensus S2e guideline recommendations for the treatment of benign symptomatic functional disorders with low-dose radiotherapy. MATERIALS AND METHODS: This overview reports on the role of low-dose radiotherapy in the treatment of functional disorders in cases of heterotopic ossification (HO) and Graves orbitopathy (GO). The most relevant aspects of the DEGRO S2e Consensus Guideline "Radiation Therapy of Benign Diseases 2014" regarding diagnostics, treatment decision, dose prescription, as well as performance of radiotherapy and results are summarized. RESULTS: For both indications (HO, GO), retrospective and some prospective analyses have shown remarkable effects in terms of symptom relief. Nevertheless, the level of evidence (LoE) and the grade of recommendation (GR) vary: LoE 1-2 and GR A-B (HO), LoE 2 and GR B (GO). CONCLUSION: Low-dose radiotherapy for benign symptomatic functional disorders has proven to be effective, according to different authors, for 25-100 % of the patients studied and therefore it may be a reasonable prophylactic and therapeutic option if noninvasive or invasive methods have been used without persistent success. For HO, a single-fraction dose of 7-8 Gy or fractionated radiation with five fractions of 3.5 Gy is recommended. For GO, single-fraction doses of 0.3-2.0 Gy, and total doses of 2.4-20 Gy/series, applied in one daily fraction are recommended.
PURPOSE: To summarize the updated DEGRO consensus S2e guideline recommendations for the treatment of benign symptomatic functional disorders with low-dose radiotherapy. MATERIALS AND METHODS: This overview reports on the role of low-dose radiotherapy in the treatment of functional disorders in cases of heterotopic ossification (HO) and Graves orbitopathy (GO). The most relevant aspects of the DEGRO S2e Consensus Guideline "Radiation Therapy of Benign Diseases 2014" regarding diagnostics, treatment decision, dose prescription, as well as performance of radiotherapy and results are summarized. RESULTS: For both indications (HO, GO), retrospective and some prospective analyses have shown remarkable effects in terms of symptom relief. Nevertheless, the level of evidence (LoE) and the grade of recommendation (GR) vary: LoE 1-2 and GR A-B (HO), LoE 2 and GR B (GO). CONCLUSION: Low-dose radiotherapy for benign symptomatic functional disorders has proven to be effective, according to different authors, for 25-100 % of the patients studied and therefore it may be a reasonable prophylactic and therapeutic option if noninvasive or invasive methods have been used without persistent success. For HO, a single-fraction dose of 7-8 Gy or fractionated radiation with five fractions of 3.5 Gy is recommended. For GO, single-fraction doses of 0.3-2.0 Gy, and total doses of 2.4-20 Gy/series, applied in one daily fraction are recommended.
Authors: L J DeGroot; C A Gorman; A Pinchera; L Bartalena; C Marcocci; W M Wiersinga; M F Prummel; L Wartofsky; C ] Marocci C [corrected to Marcocci Journal: J Clin Endocrinol Metab Date: 1995-02 Impact factor: 5.958
Authors: Jan Kriz; Heinrich M Seegenschmiedt; Amelie Bartels; Oliver Micke; Ralph Muecke; Ulrich Schaefer; Uwe Haverkamp; Hans T Eich Journal: Adv Radiat Oncol Date: 2018-02-26
Authors: Thomas Weissmann; Sebastian Lettmaier; Anna-Jasmina Donaubauer; Christoph Bert; Manfred Schmidt; Friedrich Kruse; Oliver Ott; Markus Hecht; Rainer Fietkau; Benjamin Frey; Florian Putz Journal: Strahlenther Onkol Date: 2021-04-16 Impact factor: 4.033